Qualigen Therapeutics, Inc. - Multiplikator EV/Sales QLGN

Qualigen Therapeutics generates revenue primarily through the sale of rapid blood tests, as confirmed by the historical EV/Sales trend, where the current metric is . The growth in business value is supported by the proprietary AS1411 platform, which creates a closed-loop therapy system. The stability of future supplies is guaranteed by the calibration of high-precision equipment at partner plants to meet clinical trial requirements.
qualigeninc.com - rincian analitis lan metrik utama (QLGN)

This indicator compares the total enterprise value to sales volume, excluding the impact of debt load to identify the actual market overvaluation of the asset. By analyzing the EV/Sales ratio of Qualigen Therapeutics (QLGN), an investor assesses the monetization efficiency of the distribution of diagnostic systems and drugs, where the stability of the metric confirms the resilience of supply chains and the operational profitability of Qualigen Therapeutics (QLGN) amid the diversification of production sites.